The document discusses trends in the pharmaceutical market in Southeast Asia. It forecasts strong growth in the region but identifies risks like protectionism, intellectual property issues, and pricing and reimbursement challenges. The economy is expected to outperform globally and universal healthcare is becoming more politically important. Companies need region-specific strategies given the diversity across Southeast Asian markets that are undergoing economic and regulatory integration.
Healthcare services ; pharmaceutical market of myanmarAccord Healthcare
This report consolidates the main developments of the pharmaceutical market in Myanmar over the last decade. Among the APAC Markets, Myanmar is catching the most attention after the Vietnam. The report provides in-depth information on the healthcare medical system & Pharmaceutical market of Myanmar.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
Healthcare services ; pharmaceutical market of myanmarAccord Healthcare
This report consolidates the main developments of the pharmaceutical market in Myanmar over the last decade. Among the APAC Markets, Myanmar is catching the most attention after the Vietnam. The report provides in-depth information on the healthcare medical system & Pharmaceutical market of Myanmar.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
Pharmaceutical sector is one of the most developed hi-tech sectors in Pakistan The growth of the country's pharmaceutical industry has dropped from approximately 16 percent per annum to around eight percent per annum which is a cause of concern not only for the industry but government as well. There is a need of publicly funded R&D institution. Pakistan has to create an enabling infrastructure and linkage to facilitate Pharmaceutical Industry to improve process technique. It is needed to stimulate skill development of Human Resource in Pharmaceutical R&D and to enhance nation’s self-reliance in drugs and pharmaceuticals, especially in areas of national health requirements. Providing technical support to pharmaceutical companies for export is also necessary.
An introductory overview of healthcare across South East Asia and a look at the growing healthcare trends across the region.
Download the presentation by clicking the "Save this presentation" icon above.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
Pharmaceutical sector is one of the most developed hi-tech sectors in Pakistan The growth of the country's pharmaceutical industry has dropped from approximately 16 percent per annum to around eight percent per annum which is a cause of concern not only for the industry but government as well. There is a need of publicly funded R&D institution. Pakistan has to create an enabling infrastructure and linkage to facilitate Pharmaceutical Industry to improve process technique. It is needed to stimulate skill development of Human Resource in Pharmaceutical R&D and to enhance nation’s self-reliance in drugs and pharmaceuticals, especially in areas of national health requirements. Providing technical support to pharmaceutical companies for export is also necessary.
An introductory overview of healthcare across South East Asia and a look at the growing healthcare trends across the region.
Download the presentation by clicking the "Save this presentation" icon above.
The 2016 IMS APAC Insight Magazine provide insights to unveils new areas of play, new methodologies and new geographies that are poised to disrupt the healthcare landscape in this region.
ASEAN shows a strong growth of health expenditure per capita leading by Singapore, Malaysia and Thailand. To find out more about other countries, check out our latest publication at http://bit.ly/1hmvwFq
The pharmaceutical industry will be characterised by heightened uncertainty in 2017, mainly due to inevitable changes to the politicised US health system.
Pricing is expected to remain the key issue, and providers of goods and services, especially those with questionable cost-benefit profiles, can expect further scrutiny. Emerging pharmaceutical markets are also in a cycle of under-performance compared with developed markets.
Despite all the challenges facing the healthcare sector, we nevertheless maintain a positive outlook. Investors will continue to be attracted to the robust fundamentals that support innovation and the consequential generation of high margins.
Indonesia Healthcare Landscape - An Overview, July 2014Praneet Mehrotra
A brief description of Indonesia's healthcare landscape and the challenges it faces. The country has no choice, but to attract greater investments (also importantly, foreign investments) in capacity creation.
Amid a general slowdown of the global pharmaceutical market, pharmerging markets continue to be a formidable engine of growth; across Asia, Africa and South America, these markets are boasting a CAGR of 10-14%. At the outer edges of these growing economies are markets identified by IMS Health as “Frontier Markets” – the next big drivers of growth, opportunity and even innovation.
Among the Frontier Markets, Myanmar is capturing the most attention. With the completion of parliamentary elections in early November of 2015, there are positive signs that the momentum for change and market liberalization will accelerate. Indeed, Myanmar resembles the early days of some of today’s leading Asian developing markets such as Vietnam and Indonesia. However, while understanding the similarities is certainly valuable, the temptation to merely duplicate entry strategies and market assumptions should be resisted. Myanmar’s underinvested healthcare infrastructure, sizeable talent gaps, and significant regulatory and affordability hurdles, require an informed approach, and managed expectations. Multinationals will be challenged to re-evaluate what it takes to play, and what it means to win in both the short and long term.
Understand more about the Awareness, Affordability and Access strategic framework to drive success for global pharma companies engaging with Asian Markets.
Medical Laboratory Accreditation and its utilization in Japan - Katsuo KubonoMara International
The 3rd GCC Laboratory Proficiency Conference is organized as part of the strategic orientations of the GCC Standardization
Organization (GSO) for the development of the standardization and quality infrastructure, thereby contributing to the development of commerce and industry and to the support of national economy in the GCC member states.
Since the field of proficiency testing is newly introduced in the GCC member states and as the infrastructure of laboratories has not yet taken the shape of national or regional organizations representing the laboratories and reflecting their requirements, GSO is in need of meeting with a considerable group of laboratories to explore and prioritize GCC member states’ requirements in terms of the fields which must top the list of the fields to be developed and upgraded.
Based on the study conducted by GSO during 2011 on the status of proficiency testing activities in the member states which shown that the laboratories operating in the member states are in need of a unified data center on proficiency testing activities, GSO
organized two conferences in 2013 and 2014 on the subject. The conferences scored high rates of success in terms of the selected scientific material, quality of speakers and the targeted audience.
Accordingly, GSO conceptualization of the method of coordinating and upgrading the activity of proficiency tests in the GCC member states included a recommendation on the organization of annual training courses and awareness symposia by the GSO on the fields of proficiency tests.
This year’s Conference will be held in Dubai during two days the 24th and 25th of March 2015, and will coincide with the annual Analytical Industry exhibition ARABLAB which will be held in Dubai during the period 23 – 26 March 2015.
Mera Medicare is a unique business model which has potential to revolutionize healthcare industry by changing the way customers and healthcare professionals interact with each other. MeraMedicare provides an effective-tail platform to both healthcare professionals and customers while solving their key challenges.This presentation is intended for Competitive Analysis in Indian Online Pharma Industry
This presentation was delivered in IIC - TRPC Forum: Smart Health, IoT and the Empowerment of Patients.
It includes insights from Analysys Mason's 2015 global study of trends in smart health developments, starting from the
challenges and changes in health industry, identifying the
key drivers in these early stages of telehealth development, showing the future outlook, and sharing case studies of early movers in Asia and the rest of the world.
Money Regulation In Healthcare PowerPoint Presentation Slides SlideTeam
Presenting this set of slides with name - Money Regulation In Healthcare Powerpoint Presentation Slides. Enhance your audiences knowledge with this well researched complete deck. Showcase all the important features of the deck with perfect visuals. This deck comprises of total of fourty one slides with each slide explained in detail. Each template comprises of professional diagrams and layouts. Our professional PowerPoint experts have also included icons, graphs and charts for your convenience. All you have to do is DOWNLOAD the deck. Make changes as per the requirement. Yes, these PPT slides are completely customizable. Edit the colour, text and font size. Add or delete the content from the slide. And leave your audience awestruck with the professionally designed Money Regulation In Healthcare Powerpoint Presentation Slides complete deck.
Commercialised supply of training & certification to improve quality and safe...ILRI
Presentation by Amos Omore to Conference on Climate Change Adaptation Strategies, Capacity Building and Agricultural Innovations to Improve Livelihoods in Eastern and Central Africa: Post-Copenhagen, Addis Ababa, Ethiopia, 7 – 9 June 2010
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
Medical Devices & Diagnostics Asia - Balancing Risk & Reward WhitepaperSimranjit Singh
A whitepaper from Quintiles which looks at the growth potential of Asia pacific for medical devices and the approaches to navigate the complex regulatory pathways.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
This Ipsos healthcare publication provides a summary review of market opportunities related to universal healthcare programmes in ASEAN – with a special focus on Indonesia, Vietnam and the Philippines. As each country’s population joins its national health system, extensive partnerships are needed to fill the demand for hospital beds, qualified doctors, modern equipment, quality medicine and after-sales service.
This healthcare paper takes an up-to-date look at current needs and priorities within these countries’ healthcare plans, along with an analysis of the relevant budgetary and regulatory issues involved.
Email your questions and comments about this healthcare paper to indonesia.bc@ipsos.com
In the past year, we have experienced the need and importance of a strong Healthcare sector, so if you are looking for a sign to invest in this sector, look no more, because this is it. Invest in a sector that's growing for the greater good and give your portfolio the boost it needs with ICICI Prudential Healthcare ETF.
NFO starts on May 6th, 2021.
For more on this head to https://bit.ly/3ujXO9z
In October 2014, INTEGRATED's Bill Jessee presented "Where Is Healthcare Going? And How Will We Get There?" at Iowa Hospital Association's annual meeting. The presentation focuses on the forces shaping healthcare today, the delivery system changing in response to the environment, and what this all means for hospitals and physicians.
Similar to South East Asia Pharmaceutical Markets Jamie Davies October 2014 (20)
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
South East Asia Pharmaceutical Markets Jamie Davies October 2014
1. Pharma Insight Briefings - Asia
Dynamics & Trends That Make South East Asia’s Pharma Market
Unique And Challenging
CPhI Worldwide Pre-Connect Conference, Paris, France
Thursday 9th October 2014, 14.15-15.30, Room 520A & 520B
Jamie Davies, Head of Pharmaceuticals, Medical Devices & Healthcare
www.businessmonitor.com
2. Overview
Market Forecasts
Intellectual Property
Risk/Reward Index
1 2 3 4 5 6 7 8 9 10
Protectionism
Pricing &
Reimbursement
Universal
Political Risk Healthcare
Economic Outlook Competitive
Landscape
Case Study
4. Protectionism
Image: Indonesia’s National Agency for Drug and Food
Control (BPOM; Badan Pengawas Obat dan Makanan)
• Local manufacturing requirements
• Restrictions on foreign investment
• Preferential purchasing
• Local clinical trials
BMI View: Partnerships are key
5. Intellectual Property
Image: Inspection of the Government Pharmaceutical Organization
(GPO)’s new production facility in Pathumthani Province, Thailand.
• Compulsory licences
• Regulatory data protection
• Incremental innovation
• Country-specific rules
BMI View: Regulations will improve
6. Pricing & Reimbursement
Image: Community groups and organisations from the health
sector protesting in Manila, the Philippines, about the lack of
lower pharmaceutical prices from the Cheaper Medicine Act.
• Price controls
• Promotion of generic drugs
• National drug lists
• Reference pricing
BMI View: More health economics
7. Political Risk
Population Muslim Buddhist Christian Folk religion Unaffiliated Hindu Other religion
Brunei 400,000 300,400 34,400 37,600 24,800 1,600 1,200 400
Cambodia 14,140,000 282,800 13,701,660 56,560 84,840 28,280 0 0
Indonesia 239,870,000 209,166,640 1,679,090 23,747,130 719,610 240,000 4,077,790 239,870
Laos 6,200,000 0 4,092,000 93,000 1,903,400 55,800 0 43,400
Malaysia 28,400,000 18,090,800 5,026,800 2,669,600 653,200 198,800 1,704,000 56,800
Myanmar 47,960,000 1,918,400 38,415,960 3,740,880 2,781,680 239,800 815,320 9,920
Philippines 93,260,000 10,329,300 3,453,000 73,758,760 2,398,900 4,193,260 0 93,260
Singapore 5,090,000 727,870 1,725,510 926,380 117,070 834,760 264,680 493,730
Thailand 69,120,000 3,801,600 64,419,840 622,080 60,000 207,360 69,120 0
Vietnam 87,850,000 175,700 14,407,400 7,203,700 39,796,050 26,003,600 0 351,400
Total 592,290,000 244,793,510 146,955,660 112,855,690 48,539,550 32,003,260 6,932,110 1,288,780
Source: The Global Religious Landscape - A Report on the Size
and Distribution of the World’s Major Religious Groups as of
2010, Pew Research Center.
High proportion of population
Low proportion of population
8. Economic Outlook
• ASEAN Economic Community
• Trans-Pacific Partnership
• China rebalancing
• Currency appreciation/depreciation
BMI View: A global outperformer
Five-Year Forecast For Change In Exchange
Rate Versus US Dollar (2013-18)
-20 -15 -10 -5 0 5 10 15 20
Brunei dollar
Malaysian ringgit
Singapore dollar
Thai baht
Vietnamese dong
Philippine peso
Cambodia riel
Lao kip
Indonesian rupiah
Myanmar kyat
Source: BMI
9. Universal Healthcare
Image: Health City Novena, Singapore.
• Economically and politically beneficial
• Minimum wealth threshold
• Different interpretations
• Inevitable delays
BMI View: Increasingly integral to politics
10. Competitive Landscape
Image: Singapore’s Biopolis, a biomedical R&D centre
• Widespread presence of multinationals
• Emergence of local firms
• More R&D
• Competition from India and China
BMI View: Region-specific strategy vital
11. Risk/Reward Index
Market expenditure
Spending per capita
Market growth
Urban/rural split
Pensionable population
Population growth
Patent respect
Policy enforcement
Approvals expediency
Economic diligence
Policy continuity
Lack of bureaucracy
Legal diligence
Rewards
Risks
Market Rewards
Country Rewards
Market Risks
Country Risks
Risk/Reward Index
Business transparency
Risk/Reward Index
scores 0 – 100.
O = least attractive
market; 100 = most
attractive market.
Source: BMI
12. 30
25
20
15
10
5
Risk/Reward Index
Risk/Reward Profile Of South East Asia Pharmaceutical Markets
Low Reward/Low Risk High Reward/Low Risk
Malaysia
Low Reward/High Risk High Reward/High Risk
15 20 25 30 35
Risks
Rewards
Singapore
Brunei Darussalam
Myanmar
Laos
Cambodia
Thailand
Philippines
Vietnam
Indonesia
Source: BMI
13. Case Study: Vietnam
100
90
80
70
60
50
40
30
20
10
0
Poorest
2nd
3rd
“missing middle”
4th
5th
6th
7th
8th
9th
Highest
Health Insurance Coverage In Vietnam By
Economic Decile In 2010
Source: Estimates based on data from the Vietnam
Living Standards Measurement Survey, 2010.
• Universal healthcare being introduced
• Poor enforcement
• High medicine prices
• Hospital over-crowding
BMI View: Most promising in region
14. Summary
• Strong growth forecast for South East Asia, but with risks:
o Protectionism, intellectual property, and pricing & reimbursement
• Regional economy to outperform
• Universal healthcare to increasingly become a political tool
• Companies must adopt South East Asia-specific strategies
• A diverse region undergoing economic and regulatory unification
